{"filing":{"accession_number":"0001193125-26-387858","cik":"0001802255","ticker":"GRDN","company_name":"Guardian Pharmacy Services, Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"d185380d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1802255/000119312526387858/d185380d8k.htm"},"events":[{"id":32631,"run_id":29993,"accession_number":"0001193125-26-387858","anchor_item_number":"8.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"This disclosure concerns lock-up agreements entered into by the Company with founders, executive officers, and certain employees, restricting the sale or transfer of approximately 29.9 million shares (81% of insider holdings) through September 14, 2027. While lock-up agreements are governance-related and affect capital structure and insider trading dynamics, this is a routine post-IPO governance arrangement that does not fit the specific categories of exec_appointment, exec_departure, or exec_compensation. The materiality is driven by the scale of shares locked up and the impact on share supply and insider incentive alignment, making it material to a reasonable investor's assessment of the registrant's capital structure and insider commitment.","company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35846,"accession_number":"0001193125-26-387858","item_number":"8.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This disclosure concerns lock-up agreements entered into by the Company with founders, executive officers, and certain employees, restricting the sale or transfer of approximately 29.9 million shares (81% of insider holdings) through September 14, 2027. While lock-up agreements are governance-related and affect capital structure and insider trading dynamics, this is a routine post-IPO governance arrangement that does not fit the specific categories of exec_appointment, exec_departure, or exec_compensation. The materiality is driven by the scale of shares locked up and the impact on share supply and insider incentive alignment, making it material to a reasonable investor's assessment of the registrant's capital structure and insider commitment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:08:45.029974+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35846,"accession_number":"0001193125-26-387858","item_number":"8.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This disclosure concerns lock-up agreements entered into by the Company with founders, executive officers, and certain employees, restricting the sale or transfer of approximately 29.9 million shares (81% of insider holdings) through September 14, 2027. While lock-up agreements are governance-related and affect capital structure and insider trading dynamics, this is a routine post-IPO governance arrangement that does not fit the specific categories of exec_appointment, exec_departure, or exec_compensation. The materiality is driven by the scale of shares locked up and the impact on share supply and insider incentive alignment, making it material to a reasonable investor's assessment of the registrant's capital structure and insider commitment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:08:45.029974+00:00","company_name":"Guardian Pharmacy Services, Inc.","ticker":"GRDN","filing_date":"2026-09-10"}]}